Drug Profile

Imilecleucel-T - Acer Therapeutics

Alternative Names: Autologous T cell vaccine - Acer Therapeutics; Tcelna; Tovaxin^®

Latest Information Update: 02 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Opexa Therapeutics
Developer Acer Therapeutics
Class Immunotherapies; T lymphocyte cell therapies; Vaccines
Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Multiple sclerosis

Most Recent Events

02 Feb 2026 Discontinued - Phase-II for Multiple sclerosis (First-line therapy) in Canada (SC), before February 2026
02 Feb 2026 Discontinued - Phase-II for Multiple sclerosis (First-line therapy) in USA (SC), before February 2026
20 Nov 2023 Acer Therapeutics has been acquired by Zevra Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com